Trosyd 28% cutaneous solution

Trosyd is a well-known antifungal medication specifically formulated for the treatment of nail and skin infections, such as onychomycosis and various mycoses. The brand was originally developed by the American pharmaceutical giant Pfizer, which introduced the active ingredient tioconazole to the market. Over the years, ownership of the brand has shifted as part of corporate restructuring and divestitures in the consumer healthcare sector.

In the Italian market and several other regions, the brand is currently managed and manufactured by Giuliani S.p.A., an Italian pharmaceutical company founded in Milan in 1889. While Giuliani handles the production and distribution in its primary markets, the global rights to the brand name Trosyd have historically been linked to the consumer health divisions of Pfizer and later Johnson & Johnson. As of 2024 and moving into 2026, many of these consumer brands fall under the umbrella of Kenvue, the independent consumer health company spun off from Johnson & Johnson. The product shown is manufactured in Italy, reflecting its strong local presence and the specialized production facilities of Giuliani S.p.A.